Prognostic Value of Performance Scores in Patients Undergoing Surgery for Upper Tract Urothelial Carcinoma
- Conditions
- Carcinoma, Transitional Cell (RENI)
- Interventions
- Other: No intervention
- Registration Number
- NCT06305130
- Lead Sponsor
- Kaohsiung Medical University
- Brief Summary
Aim: to comprehensively evaluate the prognostic value of preoperative ECOG-PS scores and ASA scores in patients undergoing radical nephroureterectomy (RNU) for upper tract urothelial carcinoma.
Methods: multicentered cohort study
- Detailed Description
Background:
The Eastern Cooperative Oncology Group (ECOG) performance status (PS) score and the American Society of Anesthesiologists (ASA) score are essential tools for the assessment of patients with various malignancies. However, doubts have arisen regarding their prognostic utility due to conflicting findings in limited studies. This study aims to comprehensively evaluate the prognostic value of preoperative ECOG-PS scores and ASA scores in patients undergoing radical nephroureterectomy (RNU) for upper tract urothelial carcinoma.
Materials and Methods:
This multicentered cohort study enrolled patients who underwent RNU with curative intentat sixteen institutes in Taiwan from 1988 to 2023. Univariable and multivariable regression analyses were used to determine the impact of ECOG-PS scores and ASA scores on survival outcomes and postoperative complications. Patients were categorized based on ECOG-PS scores (0-1 vs. 2-4) and ASA scores (1-2 vs.3-4) according to prior literature.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2515
- All patients received UTUC surgery and follow-up in sixteen institutions across Taiwan
- Treatment not aimed at curative intent
- Incomplete data
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Primary cohort (only one in this study) No intervention Patient data were collected from sixteen institutions across Taiwan, encompassing 6005 patients diagnosed with UTUC between 1988 and 2023. The study included all patients who underwent RNU with curative intent. After excluding those with incomplete data, a total of 2515 eligible patients were included in the final analysis.
- Primary Outcome Measures
Name Time Method Overall survival 1988 to 2023 in days
Disease-free survival 1988 to 2023 in days
Bladder recurrence-free survival 1988 to 2023 in days
Cancer-specific survival 1988 to 2023 in days
- Secondary Outcome Measures
Name Time Method Number of patients with postoperative renal failure 1988 to 2023 Those who requiring renal replacement therapy permanently
Number of patients with major postoperative complication 1988 to 2023 Clavien-Dindo classification grade higher or equal to III